Swedish Orphan Biovitrum AB, an international specialty biopharmaceutical company listed in Sweden, agreed to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition supersedes the previously announced exclusive licence agreement with Novimmune. In addition, Sobi agreed with Novimmune on options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology. The transaction value is CHF 515 million, of which CHF 400 million was previously committed in the exclusive license agreement for emapalumab.

Bär & Karrer acted as legal advisor to Swedish Orphan Biovitrum AB (publ). The team included Urs Brügger, Marc Poltéra, Raphael Wyss, Eliane Albert and Michael Neumann (all M&A and Corporate), Markus Schott (Regulatory), Laura Widmer (Employment), Jonas Bornhauser (IP) as well as Mani Reinert (Competition Law).